C12N 2310/3525
Moe, methoxyethoxy
Official title: MOE, methoxyethoxy
C12N2310/3525 (Moe, methoxyethoxy) appears on 149 US grants and 279 published applications in this corpus.
Search patents in C12N- Granted patents
- 149
- Published applications
- 279
- Assignees
- 69
- Inventors
- 293
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 2 |
| 2005 | 0 | 2 |
| 2006 | 1 | 1 |
| 2007 | 0 | 3 |
| 2008 | 1 | 1 |
| 2009 | 1 | 6 |
| 2010 | 2 | 3 |
| 2011 | 2 | 3 |
| 2012 | 4 | 4 |
| 2013 | 1 | 13 |
| 2014 | 4 | 5 |
| 2015 | 13 | 19 |
| 2016 | 8 | 18 |
| 2017 | 19 | 19 |
| 2018 | 11 | 35 |
| 2019 | 21 | 21 |
| 2020 | 13 | 19 |
| 2021 | 11 | 23 |
| 2022 | 5 | 15 |
| 2023 | 9 | 13 |
| 2024 | 6 | 27 |
| 2025 | 11 | 14 |
| 2026 | 4 | 13 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compounds and methods for reducing PLN expression22 Sep 2026US 12,742,170 B2Ionis Pharmaceuticals, Inc.
- Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases7 Apr 2026US 12,595,479 B2Children's Medical Center Corporation
- Modulation of prekallikrein (PKK) expression7 Apr 2026US 12,595,485 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating TTR expression6 Jan 2026US 12,516,319 B2Ionis Pharmaceuticals, Inc.
- Compositions and methods for modulating apolipoprotein C-III expression30 Dec 2025US 12,509,684 B2Ionis Pharmaceuticals, Inc.
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Oligonucleotides targeting gal3st124 Sep 2026US 2026/0286364 A1
- Conjugated antisense compounds and their use3 Sep 2026US 2026/0258417 A1Ionis Pharmaceuticals, Inc.
- Conjugated antisense compounds and their use27 Aug 2026US 2026/0250680 A1Ionis Pharmaceuticals, Inc.
- In vitro enzymatical rna synthesis20 Aug 2026US 2026/0242838 A1DNA Script
Most cited
By later US patents
- Interfering RNA molecules134US 7,452,987 B2Silence Therapeutics GmbH · 2008
- Conjugated antisense compounds and their use122US 9,127,276 B2Isis Pharmaceuticals, Inc. · 2015
- Antisense inhibiton of human G-alpha-12 expression77US 5,998,206 AIsis Pharmaceuticals, Inc. · 1999
- Interfering RNA molecules77US 9,222,092 B2Silence Therapeutics GmbH · 2015
- Modulation of dystrophia myotonica-protein kinase (DMPK) expression69US 9,765,338 B2Ionis Pharmaceuticals, Inc. · 2017